Inhaled Insulin Just Got FDA-Approved for Kids With Type 1
Taking Control Of Your Diabetes® - The Podcast!Show Notes
In this episode of the TCOYD Podcast, Dr. Steve Edelman is joined by pediatric endocrinologist Dr. Anna Cymbaluk, along with Philip and his father Jim, to discuss the recent FDA approval of Afrezza inhaled insulin for children and adolescents living with type 1 diabetes. Dr. Cymbaluk served as an investigator on the INHALE-1 trial, while Philip participated in the study himself, providing a unique real-world perspective on what it is like to transition from injections to inhaled insulin, and Philip’s dad, Jim provided the parent perspective as well as addressed parental concerns that might have arisen. The conversation focuses on the INHALE-1 study and the unmet challenges that continue to exist around mealtime insulin dosing in pediatric diabetes care. Dr. Cymbaluk reviews the trial design, glucose outcomes, safety data, patient satisfaction findings, and the practical realities of introducing inhaled insulin into everyday diabetes management. Philip and Jim share how Afrezza impacted school, sports, social situations, and the day-to-day burden of diabetes, particularly around pre-bolusing, corrections, and avoiding multiple injections throughout the day. Dr. Edelman and Dr. Cymbaluk also explore how Afrezza is dosed, how inhaled insulin differs from injected insulin, who may be a good candidate, and where it may fit alongside pumps and automated insulin delivery (AID) systems. For families looking for more flexibility, fewer mealtime barriers, and another option in the diabetes toolbox, this episode provides an honest look at the benefits, limitations, and real-world experience of inhaled insulin in children and teens.
Key Topics • The FDA approval of Afrezza for children and adolescents living with type 1 diabetes • The design and results of the INHALE-1 pediatric clinical trial • Patient satisfaction and quality-of-life outcomes from the study • The challenges of pre-bolusing and mealtime insulin management in children and teens • How inhaled insulin compares to traditional mealtime injections • Dosing strategies, cartridge sizes, and insulin conversion considerations • Using Afrezza for corrections, meals, and post-meal dosing • The role of continuous glucose monitoring (CGM) when using inhaled insulin • Safety findings, lung-function monitoring, and cough management • Who may be a good candidate for Afrezza—and who may not be • Benefits for active children, athletes, and those participating in sports • Social situations, injection avoidance, and reducing the burden of diabetes management • Using Afrezza alongside insulin pumps and automated insulin delivery (AID) systems • The importance of having more treatment options to individualize diabetes care Supported by an unrestricted educational grant from MannKind Corporation
Subscribe for practical diabetes management tips, technology updates, and treatment breakthroughs that help people with diabetes live healthier, more flexible lives. More diabetes resources: Website: tcoyd.org Blog: tcoyd.org/blog Podcast: tcoydthepodcast.transistor.fm Instagram: / tcoyd Facebook: / tcoyd Stay connected! Sign up for our monthly newsletter here! Support TCOYD's educational programs: tcoyd.org/donate
★ Support this podcast ★
More from Taking Control Of Your Diabetes® - The Podcast!
What if you could take your basal insulin once a week instead of every day? Once-weekly basal insulin has arrived, offering a new approach that could make insulin therapy simpler while providing glucose control comparable to daily basal insulin. In this episode, Dr. Steve Edelman is joined by Dr. Athena Philis-Tsimikas, a leading diabetes researcher who has been directly involved in clinical trials of once-weekly basal insulins. Together, they explain how these ultra-long-acting insulins work, how a single injection can provide steady background insulin throughout an entire week, and what studies have shown when once-weekly insulin is compared with traditional daily basal insulin. The conversation gets practical with how once-weekly insulin is started, adjusted, and switched from daily basal insulin. Dr. Edelman and Dr. Philis-Tsimikas discuss the dosage differences with once-weekly basal insulin, how concentrated insulin keeps the actual injection volume small, and how fasting glucose can help guide dose adjustments. They also discuss what happens if you miss a dose and why reaching a steady state is an important part of understanding how these longer-acting insulins work. They also dive into the clinical trial results, including A1C, time in range, and hypoglycemia. In studies of people living with type 2 diabetes, once-weekly basal insulin provided similar A1C lowering to daily basal insulin without an increase in hypoglycemia. They also explain why the story is different for people living with type 1 diabetes, where studies found higher rates of hypoglycemia with weekly basal insulin, and what that means for its use in the United States. Finally, Dr. Edelman and Dr. Philis-Tsimikas look at how once-weekly insulin could make diabetes management easier. Going from seven basal injections a week to just one could help reduce some of the daily burden of diabetes and make it easier to consistently take your insulin. They also explore using weekly insulin alongside GLP-1 medications, potential combination therapies, cost and access, and what we still need to learn as these newer insulins move from clinical trials into everyday diabetes care. Key Topics: How once-weekly basal insulin works Once-weekly vs. daily basal insulin Starting, dosing, and adjusting weekly insulin Why weekly insulin doses may look surprisingly large A1C, time in range, and hypoglycemia results What to do if you miss a weekly dose Once-weekly insulin in type 1 vs. type 2 diabetes Who may benefit from once-weekly insulin? Reducing the burden of daily injections Using once-weekly insulin with GLP-1 medications Future insulin and GLP-1 combination therapies Cost, access, and real-world considerations What the future of basal insulin could look like This episode was supported by Lilly. ✨ Subscribe for practical diabetes management tips, technology updates, and treatment breakthroughs that help people with diabetes live healthier, more flexible lives.
Managing type 2 diabetes can change over time, but having the right information for your patients can make those changes feel a lot more manageable. CGM can help your patients see what’s happening with their blood sugar and guide what comes next.
Chronic kidney disease (CKD) is one of the most common complications of diabetes, but here’s the tricky part: you can have it for years without feeling any symptoms. The good news? Kidney disease can often be detected early, and with the right screening, treatments, and lifestyle changes, its progression can be dramatically slowed. In this episode, Dr. Steve Edelman and Dr. Jeremy Pettus are joined by nephrologist Dr. Bethany Karl to break down what everyone with diabetes should know about kidney health. Dr. E also steps into the patient seat to share his own experience living with chronic kidney disease, from discovering it without symptoms to navigating kidney tests and newer treatments. Together, they explain the two simple tests that can uncover kidney problems, why blood pressure and cardiovascular health matter, and how today’s growing toolbox of medications is giving people with diabetic kidney disease more reasons for hope.
Hot flashes, blood sugar swings, brain fog... is it menopause, diabetes, or both?
Have you or someone you know been diagnosed with type 2 diabetes, only to discover later it was actually type 1? You're not alone.